The nitric oxide/cGMP signaling pathway in pulmonary hypertension

James R Klinger

doi:10.1016/j.ccm.2006.12.002

The nitric oxide/cGMP signaling pathway in pulmonary hypertension

Clin Chest Med. 2007 Mar;28(1):143-67, ix. doi: 10.1016/j.ccm.2006.12.002.

Author

James R Klinger¹

Affiliation

¹ Division of Pulmonary Sleep and Critical Care Medicine, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903, USA. james_klinger@brown.edu

PMID: 17338933
DOI: 10.1016/j.ccm.2006.12.002

Abstract

This article briefly reviews the background of endothelium-dependent vasorelaxation, describes the nitric oxide/cGMP/protein kinase pathway and its role in modulating pulmonary vascular tone and remodeling, and describes three approaches that target the nitric oxide/cGMP pathway in the treatment of patients with pulmonary arterial hypertension.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Cell Proliferation
Cyclic GMP / physiology*
Endothelial Cells / physiology
Humans
Hypertension, Pulmonary / physiopathology*
Nitric Oxide / physiology*
Piperazines / therapeutic use
Purines / therapeutic use
Signal Transduction / physiology*
Sildenafil Citrate
Sulfones / therapeutic use
Vasodilation / physiology
Vasodilator Agents / therapeutic use

Substances

Piperazines
Purines
Sulfones
Vasodilator Agents
Nitric Oxide
Sildenafil Citrate
Cyclic GMP